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Cataract, the leading cause of blindness, is currently treated only by surgery. 
Cataract carries risk of complications and its management increases economic 
burden. Thus, development of pharmacological options with anticataract 
effects is important. Oxidative-nitrosative stress, non-enzymatic glycation 
and osmotic stress underlie cataractogenesis. Since tocotrienol possesses 
biological properties that may suppress pathophysiological mechanism of 
cataractogenesis, we investigated its anticataract effects in rats. Tocotrienol 
was formulated into two widely used colloidal drug delivery systems, 
microemulsion and liposome, due to its poor aqueous solubility. Firstly, the 
dose-dependent effects of microemulsion of tocotrienol on cataractogenesis 
were studied in galactose-fed rats to determine the most effective dose of 
tocotrienol. Different concentrations of tocotrienol were applied topically 
twice daily from three weeks prior to galactose diet and continued for four 
weeks along with galactose diet. Cataract progression was monitored and after 
euthanization, lenticular oxidative stress was measured. Subsequently, using 
the most effective dose, anticataract efficacy of microemulsion and liposomal 
formulation was compared in galactose-fed rats. Additionally, ocular tissue 
distribution of a lipophilic dye using these formulations was studied. For this 
distribution study, single drop of solution or formulation containing lipophilic 
dye was applied and animals were euthanized at different time points. 
Eyeglobes were dissected, cryosectioned, viewed under confocal microscope 
Glaucoma, a common cause of optic neuropathy, is associated with elevated 
intraocular pressure (IOP) and is the leading cause of irreversible visual 
disability. Steroid-induced glaucoma, a common type of secondary glaucoma, 
is also associated with elevated IOP (steroid-induced ocular hypertension 
(SIOH)). SIOH and glaucoma are currently treated with antiglaucoma agents, 
which often have suboptimal efficacy and are associated with adverse effects. 
The objective of this study was to determine if topical application of trans-
resveratrol reduces IOP in rats with SIOH and to investigate its mechanisms 
of action. This study was divided into in vivo and in vitro studies. In the in 
vivo study, we evaluated the oculohypotensive effects of topical trans-
resveratrol in normal and SIOH rats and investigated the role of adenosine 
receptors (ARs) and transforming growth factor-β (TGF-β) signalling in the 
IOP lowering effect of trans-resveratrol. Involvement of AR was studied 
by observing the IOP changes in response to trans-resveratrol after pre-
treating SIOH animals with AR subtype-specific antagonists. The study also 
investigated phospholipase C (PLC) activation, extracellular regulated kinase 
1/2 (ERK1/2) phosphorylation and increased matrix metalloproteinases 
(MMPs) secretion in the aqueous humour (AH) as mechanism of resveratrol-
induced oculohypotension in SIOH rats. In vitro studies evaluated the effect 
of trans-resveratrol on cellular signalling pathways of ARs and TGF-β in 
primary human trabecular meshwork cells (HTMCs). Single drop of all 
concentrations of trans-resveratrol produced significant oculohypotension in 
normotensive rats and 0.2% concentration produced maximum IOP reduction. 
Twice-daily topical application of trans-resveratrol 0.2% for 21-day in SIOH 
rats resulted in significant and sustained IOP reduction. This was associated 
and analyzed. Lastly, mechanisms of anticataract effect of tocotrienol 
were studied in the rat model of streptozotocin-induced diabetes, which is 
a closer representation of human diabetic cataract. Using this model, the 
effects of tocotrienol on lenticular polyol pathway, oxidative and nitrosative 
stress, NFκB signaling pathway, ATP and ATPase content, calpain activity 
and proteins levels were studied. In dose-response study, 0.03 and 0.02% 
tocotrienol-treated groups showed slower cataract progression compared to 
vehicle-treated animals with reduction of lenticular oxidative stress. Faster 
cataract progression and higher oxidative stress were seen in rats treated 
with higher concentration of tocotrienol compared to vehicle-treated group. 
Both microemulsion and liposomal formulations showed similar anticataract 
efficacy. In ocular distribution study, better intraocular distribution was 
observed following single drop application of lipophilic dye in microemulsion 
compared to liposome and solution. In rats with streptozotocin-induced 
diabetes, tocotrienol delayed the progression of cataract and this anticataract 
effect was associated with reduction of lenticular oxidative-nitrosative 
stress, NFκB activation, iNOS expression, lens polyol levels, and restoration 
of the ATP and ATPase levels, calpain activity and lens protein levels. In 
conclusion, topically applied tocotrienol shows anticataract effects in rats by 
reducing oxidative-nitrosative stress and restoring the lens polyol levels, ATP 
and ATPase levels, calpain activity and lens protein levels.
with significantly higher AH MMP-2 level; significantly reduced trabecular 
meshwork (TM) thickness and increased number of TM cells. Treatment 
with trans-resveratrol also significantly increased the ganglion cell survival 
and reduced retinal oxidative stress. Pretreatment with adenosine A1 receptor 
antagonist inhibited the oculohypotensive effect of resveratrol. The use 
of A1 AR, PLC and ERK 1/2 inhibitors also reduced resveratrol-induced 
MMP-2 secretion. These results were further supported by in vitro study 
that demonstrated that ERK1/2, PLC and MMP-2 secretion by HTMC is 
stimulated after resveratrol treatment and these effects are associated with 
upregulation of A1AR gene expression.  Topical trans-resveratrol also 
produced significantly raised plasminogen activator levels and combined 
TGF-β2+resveratrol treatment caused significant upregulation of inhibitory 
SMAD7 when compared to TGF-β2-only treated group. Hence, it could be 
concluded that trans-resveratrol-induced oculohypotension in SIOH rats 
involves its agonistic activity at the A1AR leading to PLC activation, ERK 
1/2 phosphorylation and increased MMP-2 secretion. Increased MMP-2 
secretion seems to cause changes in TM favourable for AH outflow leading 
to reduced IOP. Trans-resveratrol-induced oculohypotension could also 
be attributed to increased level of plasminogen activators, which seems to 
result from increased expression of inhibitory SMAD7, a TGF-β2 signalling 
molecule. Although current study, for the first time, has clearly demonstrated 
the significant effects of topical trans-resveratrol on IOP in rats with SIOH 
and some of the underlying mechanisms; further investigations are needed to 
fully understand the mechanisms of action of trans-resveratrol and to explore 
its potential as a future antiglaucoma agent.
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